EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSAMXG00000036720
Gene Symbol: GABRA6
3 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSAMXG00000038052
Gene Symbol: GABRB2
4 Cross references
145 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSAMXG00000036347
Gene Symbol: GABRB2
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSAMXG00000012837
Gene Symbol: GABRB3
3 Cross references
199 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSAMXG00000015087
Gene Symbol: GABRD
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSAMXG00000041587
Gene Symbol: GABRG1
3 Cross references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSAMXG00000012802
Gene Symbol: GABRG2
3 Cross references
213 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSAMXG00000040268
Gene Symbol: GABRG3
4 Cross references
222 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSAMXG00000005133
Gene Symbol: GABBR1
3 Cross references
203 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSAMXG00000011615
Gene Symbol: GABBR1
3 Cross references
191 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSAMXG00000042980
Gene Symbol: LOC103033594
3 Cross references
186 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSAMXG00000010353
Gene Symbol: LOC103041611
2 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).